Immunization Against Bacterial Diseases of the Intestine (2000)

More than two thirds of the world's infants and children live in less developed countries, often in conditions in which the unavailability of potable water and sanitation and of refrigeration for foods fosters the transmission of enteric pathogens. In such areas, bacterial enteric pathogens are common causes of infant diarrhea, dysentery in toddlers, and enteric (typhoid and paratyphoid) fever in school age children. Whereas many bacterial pathogens have been identified as causes of diarrheal disease during the past 25 years, a relative few are cumulatively responsible for the majority of disease of public health importance. Several of these have been targeted as priorities for the development of new or improved vaccines, including:Vibrio cholerae O1 and O139 (causes of epidemic and pandemic dehydrating diarrhea);Shigella (the most common etiologic agent of dysentery); enterotoxigenic Escherichia coli (the second most common cause of dehydrating infant diarrhea, after rotavirus); and, Salmonella enterica serovar Typhi (S. Typhi, the etiologic agent of typhoid fever) (1). If optimal vaccines against these infectious agents could be delivered to the pediatric populations at risk, the global burden of enteric infections could be greatly diminished. Other than Shigella, these enteric infections rarely pose a problem for children in the industrialized countries of North America and Europe, unless they travel to developing areas of the world. On the other hand, as a consequence of animal husbandry, mass food processing and fast food practices, a bacterial pathogen of particular importance in the industrialized countries, enterohemorrhagic E. coli (EHEC; also called Shiga toxin–producing E. coli [STEC]), has emerged (2). Although the need for an EHEC vaccine has been controversial, a few EHEC vaccines are in early development (3–5 0. This review covers in depth the vaccines against cholera, shigellosis, enterotoxigenic E. coli (ETEC) diarrhea, and typhoid fever, and, in addition, briefly mentions vaccines against enteropathogenic E. coli (EPEC), enteroaggregative E. coli (EAggEC), Campylobacter jejuni, and Helicobacter pylori. A common motif that will emerge is how the development of modern vaccines against bacterial enteric pathogens has depended extensively on advances in mucosal immunology, bacterial pathogenesis, and host–parasite interaction. Rather than recount in depth the pathogenesis of each bacterial enteropathogen, specific salient features are cited to illustrate how they have influenced vaccine development strategies. The bacterial enteric pathogens exhibit distinct pathogenetic themes in relation to the gut mucosa. For example, V. cholerae O1 and ETEC are noninvasive organisms that colonize the proximal small intestine where they adhere by means of fimbrial attachment factors and elaborate enterotoxins that result in net secretion (6,7). A second theme is exemplified by Shigella, which initially elaborates one or more enterotoxins (depending on their serotype) that are active in the small intestine ) 8–11), but then invades the mucosa of the distal ileum and colon, initially through M cells overlying the gut-associated lymphoid tissue (GALT) (12,13). Shigella induces intense mucosal inflammation characterized by a profligate influx of polymorphonuclear leukocytes and mucosal ulcerations and microabscesses. Demonstrating yet another motif, Salmonella enterica serovar Typhi results in a generalized infection of the GALT, reticuloendothelial system, and gall bladder. S. Typhi invades the mucosa through both M cells and enterocytes, becomes engulfed by macrophages, enters the lymph and then the blood circulation, and is filtered by fixed macrophages in the reticuloendothelial system, including the liver, spleen, and bone marrow (14). After a rather long incubation of 8 to 14 days, clinical illness begins, accompanied by persistent low-level secondary bacteremia. The most prominent site of disease is the ileum where grossly swollen Peyer's patches are noted. The Vaccine Development Paradigm Candidate vaccines are evaluated in a progressive, stepwise fashion, in the the for the the and of a the is children or in children. to more on and and to the and such as and of live vaccines are in that the of a vaccine a of the vaccine one that be for and of or of clinical are to the of and are The vaccine development is characterized by of in the vaccine a small the of and a of This be in as the the vaccines in The of be as for which one or a few need be targeted typhoid and have the In vaccines developed to and ETEC have a to a of or and more and populations for the of typhoid vaccines and children in developing countries where typhoid fever is or industrialized countries such areas, and clinical In most areas, the of typhoid fever in children. in a few in which blood of and children have been a of S. Typhi disease has been The clinical disease is often in these children of S. Typhi that a to have emerged and and of development more and a of in typhoid and S. Typhi is a pathogen that the small intestine is by M cells and to the where is by S. Typhi also be by enterocytes, in which they in the of the the are the they an influx of macrophages that the typhoid S. Typhi has that to the macrophages in which they typhoid fever is characterized by fever, and secondary bacteremia. clinical of S. Typhi a the which the by to which they are during the secondary of the long most have at the of clinical illness more is a of including and of the that against typhoid fever the of of and against typhoid they are In including by and S. Typhi and In the two typhoid S. Typhi as an vaccine and as a the vaccine In of that both vaccines to a of In in of an of during of and a during of In a in a of during of Although the and vaccines both an the of these vaccines is are to but is for of and in developing countries they be through the other pediatric The and vaccines each by distinct a that induces a of and but typhoid vaccines are to these in infants and Vaccine is less in infants in as a to to a as a to and A vaccine of to A and in as as in and children. The by a of is in a in two be to the of the and new typhoid fever of S. Typhi, (the of are of of these have been evaluated in clinical This the for Vaccine Development of the of of in and that in the the on and that are in in to in and a of in as as and for The vaccine and against S. Typhi and and secretion in the of S. Typhi and that S. Typhi vaccine blood on through 8 after in of the The blood a few after and then on and or after and the is that the blood vaccine organisms to the reticuloendothelial system, to the of typhoid fever to the secondary that Although vaccines such as and result in a for of that in a that as a S. for and that such as live a in has been to more than in and clinical is as as in to is for and is in cause in is to to clinical in pediatric in areas and to be evaluated in a as a live typhoid vaccine The is for Salmonella to of macrophages, and of S. are in S. Typhi which a in has been evaluated in a clinical in in which and in and and cells This in a global and in a that is of Salmonella to in a clinical but less than and and vaccines each by distinct is to that a of be both and the other and be and the modern vaccine of S. Typhi that in have to as vaccines This is in of typhoid fever In gall of S. Typhi of for these the that the of is in relation to such as and at two are in The is that the typhoid are in such as blood and to bacterial but is the their that by a live vaccine be that the of in the against typhoid The of S. Typhi the for and of of the of the most in the of a in which which of in and is more against S. Typhi in a that the of will clinical and Although more than of V. cholerae are the early O1 as the cause of and of dehydrating The of cholera, and as as children. clinical in the is one of the few bacterial that is of pandemic the pandemic by V. cholerae O1 on the of has to the Several in the of the illustrate the importance of and public health the of to America in after a of and to more than by the of in in in and the in of epidemic in the for the by a V. cholerae other than O139 populations for the of the new vaccines of in areas in the of children in areas, and industrialized countries and epidemic areas of the developing world. and The pathogenesis of V. cholerae O1 infection has been and have been is a of a pathogen that the mucosa yet cause the of The site of is the proximal small intestine where to the adhere to by means of and elaborate and other are by a The of has been in by the of as to 25 of (14). V. cholerae O1 as two and Whereas is during the past has been to the where has each of O1 two and In in that vaccine development an of clinical O1 of one to against the in have also the of an clinical of O139 In in the in during a both of O1 that an of to against to or In in these an clinical of less and against and against these that against be live vaccines they V. cholerae O1 of is that the by a clinical of infection is by against the and other is on which other are most is to to the of against O1 is is that as a for that of after V. cholerae O1 are against the O1 the against is a and be for V. cholerae O1 to is in against the modern vaccines have been by in a of countries is a vaccine of V. cholerae O1 in the of vaccine The other vaccine is a of V. cholerae which is as a live vaccine of these two vaccines Vaccine This vaccine a of and V. cholerae a of and of of an early of the vaccine the during the of and during of in a in in the have one of the in the two in the after of the a of the of that early of the The results to the of mucosal The which a to has been to be by and as a to 14 have been that on the of the of the and one that on the of an at and after the of the of the vaccine on a small of a of against epidemic in the of to a of transmission after that in a of disease In in a of in that children as as two of the vaccine during a of against that by or by active after the of a of vaccine the of including against in and in the of the of the of in a that of in the the of the the after of of vaccine then to of in the in the after of the of vaccine in The vaccine or is in countries and in and The vaccine is in a of water an in two a is after or Vaccine vaccine has been by V. cholerae O139 to the O1 in a in a of the vaccine and to in and to both O1 and O139 in of to both O1 and The O1 in of the O1 live vaccine by V. cholerae O1 of the the A of and by the A a to is a vaccine the and Vaccine in a of and in North America is the is for by the and The and of a of vaccine in as as and as as of including has been in of clinical active more than in many countries in Europe, and North America has been on of in in in North A of on against V. cholerae O1 of or is against and by or In these V. cholerae O1 of or is as early as 8 after and for at (the and The and of are of one has been in a developing to the of a of in conditions in an In that in North pediatric and a of vaccine or during of the vaccine in vaccine of in an in relation to blood In an vaccine in relation to blood of blood by vaccine vaccine few in two in in the of after to a the In but one of the the been less than after a of in the a of in North in in the that have been in of in developing countries in industrialized has been a to the to V. cholerae in blood of blood for the development of a V. cholerae O1 populations in conditions of blood or V. cholerae O1 live vaccines, including and vaccines, are less to children in conditions in countries than to children in industrialized countries for in and This also of live vaccine in and children in conditions in and America of in children and in to a of than the that is in North and a to of children in countries by live factors that to have been including small bacterial and infection in in developing countries and many children have and The and to in a in which to to proximal small small in children that at small as the of and a in the small and the for A of on the to could result that elaborate that V. cholerae O1 the be have and in the mucosa an gut by cells overlying lymphoid tissue and the that to the in in conditions in less developed In in children infection to two of or The then a of and For of blood in the in the the for of blood a than The of children to be of the to bacterial enteric vaccines in relation to the of the have been to the and are Several live vaccines that have been developed have been in countries, including live typhoid and live vaccines is in a to of infants and a vaccine in a and in and of the to vaccine and the other in After of a of at and after each The of which of two one vaccine and the other after the of live typhoid which the through for children and in the This of for children in and in the and infant age a problem of the and infants and of the infants to at of the vaccine (the This to and infant a of an infant or at of the second that at of the the on an for and public health new vaccines of the of modern unless be to to the of these vaccines will be This is to be a problem for live bacterial vaccines, these are as of organisms and of or other against the of The vaccine in the or of after of vaccine of after of a of in and a of the vaccine to the of the In that in the of a of is as to result in as or more of the been This is by a of the the of by the of the vaccine by the children. in infants and the of vaccine organisms to is to be less than the in the vaccine A salient of is that or of are in of of of the vaccine In the clinical in infants in a second of vaccine to one of the Whereas of infants and on after the of these after the second of vaccine This that the have that of the after to the vaccine Other V. cholerae O1 and O139 Vaccine other V. cholerae O1 vaccine have been that and in small clinical in including and A vaccine evaluated in a in in O139 and have also been to be and in of and and be in the of water to a vaccine the two of the of are The and the Typhi are as as these vaccines are and has been a in of Shigella as an public health problem In has been to the of in by dehydrating In Shigella, which causes is by that the of Shigella that the is including in developing countries, of which result in and in industrialized countries less than of age for of and of to the is in children to of are or of Shigella S. S. and S. S. and vaccine development strategies. The of Shigella that are and are and of these are S. in developing countries, and and in industrialized Shigella is the pathogen by a by S. a problem in in industrialized countries that practices, such as children in and or in In many of diarrhea, Shigella is the second most common pathogen after ETEC and causes a more clinical disease S. the Shiga is the in that causes clinical disease accompanied by such as elaborates Shiga and has the to cause that through many countries of Shiga dysentery in and have been by that to most populations for of vaccine and children in developing countries, and in industrialized countries, such as children in where has been A and vaccine is also to epidemic Shiga and In most shigellosis, an of the of dysentery that is characterized by of blood and of S. infection in in the that small secretion is responsible for the of and the of an enterotoxins two Shigella which is by the S. is by a on a in the and of an A and Shigella is by a on the by by Shigella that have to vaccine pathogenetic of Shigella is to M cells and cells by a to intense mucosal inflammation This by Shigella M which are by the on M cells or to of the and of the The and the of by a bacterial called are to the of the ileum and where they are by the Shigella the by the of and enters the by Shigella causes of the macrophages in the to the of and which an intense polymorphonuclear and of leukocytes through the to the and the infection by the of the in and in and in the that a of is by an Shigella infection to the to Shigella is specific and in many specific and is in by at the against be that these are for the of such as of and also a in against Vaccine that is is to vaccines for by of the most Shigella to The is that of the the mucosal the by the bacterial early on A vaccine of S. to A and in in In a small a of the vaccine against S. disease in the of an to vaccines to diarrheal disease and dysentery by have been to the and of S. and S. vaccines in children to of age in In these pediatric a The of each vaccine a in The second a in the S. vaccine but in S. A of these vaccines is in pediatric in that will are Shigella vaccines in children and of will be as has been the that of Shigella as and live and of Shigella as live during a In as as vaccines to be and of for of a of vaccine to for an the have to of to modern of Shigella that as live In years, as in the that these have S. the in a vaccine that a in the that the of the and which the of clinical of in of and in one the a including fever, and at these the the in a they a to that a Although against of of against more of characterized by fever and dysentery of of on the clinical in these to the to and on other live vaccines in developing countries, such as live which that is an these that be by children in developing are S. that a in a a in the in S. in for vaccine to at diarrheal and to S. be by an in in In and cells and at a of at a of of including fever and dysentery the Although clinical the clinical a S. In their to more vaccine that a in which the of S. to in a as the these to a of vaccine that other in to in and which in and evaluated in clinical This of in the most live Shigella vaccine development of fever or and a few diarrheal which to the on the clinical of S. vaccine a Shigella vaccine is that S. S. S. S. and S. S. a or the other S. and and has been in a a vaccine Shigella be to against the most that cause disease are of that are and the of to the as a of the most of has been to the of S. and S. After in and in which both and of in mucosal and clinical In in both and S. and S. and in mucosal and particular that the a vaccine is to be by of infants and children in developing countries more of a at a of such children E. and E. coli is a cause of dehydrating infant in the developing and is the most common cause of In areas, infants and have to of ETEC the to of populations for ETEC vaccines infants in areas and less developed and the pathogenesis of ETEC attachment of ETEC to the proximal small mucosa by means of fimbrial factors and the of or enterotoxins to The of ETEC are many of fimbrial and or vaccines against of ETEC pathogens. is that such will be and results of in that ETEC the infections ETEC results in against ETEC In developing countries, infants and children often have two to clinical ETEC diarrheal during the of the of ETEC The in in areas is the result of rather than to other industrialized countries where pediatric ETEC is have of of ETEC industrialized countries in less developed countries for at a have of ETEC of ETEC than to ETEC to be by against and a small after in a few that is against ETEC fimbrial a vaccine fimbrial by the most ETEC pathogens. The most common fimbrial of ETEC are and the the and of is a coli and the of or in or and the of and or in or and are less The of by ETEC the and and have been on the majority of ETEC in to of that elaborate both and enterotoxins these they are on to of a small of these a ETEC vaccine and against the majority of ETEC in most If an of is could in the of the less fimbrial and be in vaccines to the of Vaccine the vaccine is one that of ETEC in the of The ETEC vaccine developed by ETEC which the fimbrial such ETEC against the against and against development of the vaccine Candidate vaccines to enterotoxigenic E. coli the a ETEC vaccine developed of in ETEC the most an for against ETEC both in an and The vaccine by an ETEC vaccine in E. coli and by the ETEC in of the and of vaccine in and that the vaccine is and against the of the vaccine in most and clinical ETEC vaccine in and the vaccine to be and of vaccine or E. coli to children to in the of in these an against in and against in on the of the vaccine are in and and a of the of vaccine is in in children to of E. coli as against E. The of live ETEC as vaccines in clinical a E. coli and but that and A in the intestine and against ETEC and as as and one a of E. coli the fimbrial and an such as or by Several have that have greatly exhibit yet in animal and as mucosal for of the most and by the of a ETEC by that to the site the A of The of the in ETEC the by in the A and in the and each distinct and as an and as an a vaccine more for two the or and of these by E. coli and Shigella live Salmonella or Shigella E. coli Shigella and Salmonella be as live vaccines to ETEC fimbrial and and to the The of Shigella as live to and of ETEC and mucosal to has been in a the for clinical A live vaccine against both Shigella and ETEC is developed on the that be Shigella ETEC fimbrial factors and a ETEC pathogen In the vaccine will Shigella (S. S. S. and S. each two ETEC and of the ETEC and the of the to against Shigella in a Other E. Several other ETEC vaccines have been in but development of or other in and an E. is during the of the in a disease of pathogenesis have identified that is that the of against these could against The of the by the the by a and the of to as to or attachment of against the of that in is that these could to the that be by to vaccines are the need to or infants to during the of vaccine development Although is as a cause of diarrheal disease in the disease burden has been to be to specific by in areas such as is to be an cause of In an infection in an clinical diarrheal infection by against a for vaccine in the of have developed and in clinical an vaccine a mucosal The development of of vaccines is by a to a of infection has been the of including the clinical characterized by and to and are in more than of of exhibit in their which on these as responsible for in of are vaccine For of the for for as vaccine is to a vaccine In developing countries, infection is early in and is the of and vaccine development are Candidate vaccines live and or be to children in developing In the developed countries of the where pediatric populations have the of enteric and health have the the global has a in of new in where the disease burden of disease and of infections is few countries have these vaccines their on in and where typhoid fever is a public health has as yet typhoid fever on the of or as as two the need to and to of for and development of vaccines by developing the for and in The the and the the and and the the vaccine and of the of is a for The of the a of the and that have been that by the will have A of will be to burden a and fever vaccine for the developed countries of the world. for countries for the of vaccines the for a less than of less than and for the of or If is in and fever vaccines in developing countries, will then be vaccines, vaccines, and typhoid fever vaccines, where conditions their The past has advances in the development of new and improved vaccines against the most bacterial enteric infections that pose a burden of and for the world's children. Several of these vaccines that are development a of modern to that are to the global public vaccine the or in at the for Vaccine Development of the of of and are and live vaccine are to the and Vaccine is in countries as a the or The to typhoid vaccine are by of to the development of S. vaccine to these vaccine by of and and by the of and